Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Panel's Price Ceiling Reference Baffles Device Firms

Executive Summary

In a rather odd move, a key Indian expert panel concerned with trial-related approvals has outlined pricing restrictions in the device space, keeping industry on tenterhooks about potential implications, if any. The move comes after recent price-cap plans were announced in the segment.

You may also be interested in...



The BRIC/MIST Playbook: Flexibility And Sticking It Out

Innovator firms will need more than just sharp business strategies to tap into the high potential but fluid pharmaceutical markets in the BRIC/MIST countries (Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey). Flexibility well beyond pricing and the ability to wait it out till the rewards creep in are vital in these markets.

India Regulatory Diary: Marketers Co-Accountable For Lapses In Manufacturing Quality

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums

Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.

Topics

Related Companies

UsernamePublicRestriction

Register

MT104100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel